Dyno Therapeutics announced a collaboration and license agreement with Roche to apply Dyno’s CapsidMap™ platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies. Under the terms of the agreement, Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics, which it acquired in 2019 for $4.8 billion, will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids. Dyno will receive an undisclosed upfront payment and if successful, is eligible to receive additional payments during the research phase of the collaboration as well as clinical and sales milestone payments and royalties for any resulting products. The aggregate potential value of future milestone payments to Dyno may exceed $1.8 billion.
“This new partnership represents Dyno’s largest collaboration to date, and we are excited to work with Roche and Spark Therapeutics to expand the frontier of gene therapies for the central nervous system and liver. The Dyno, Roche and Spark teams share a bold vision for gene therapy and believe that enhancing vectors that deliver these therapies is key to developing new treatments for patients in need,” stated Dyno’s CEO and co-founder Eric Kelsic, Ph.D. “Partnering is a fundamental element of Dyno’s business strategy, and the continuing interest by leading gene therapy developers is accelerating our growth plans and positive impact on patients.”
Dyno Therapeutics launched from stealth mode in May of 2020, along with partnership agreements with Novartis and Sarepta Therapeutics to bolster gene therapy development for ocular and muscle diseases, respectively.
Dyno’s proprietary CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion and manufacturability. By building a massive and detailed map of synthetic AAV capsid sequence space, Dyno intends to quickly navigate the landscape to find enhanced gene therapy vectors with transformative potential.
“We strongly believe in the potential of gene therapy and are excited to bring together experts from Roche, Spark and Dyno to develop next-generation gene therapies. Dyno’s innovative AI-powered approach to designing optimized AAV vectors will further complement and build on our progress in gene therapy. We look forward to leveraging Dyno’s technology to develop new, innovative treatments for patients across CNS and liver-directed therapies,” said James Sabry, Head of Roche Pharma Partnering.